Bio-Path (NASDAQ:BPTH) Issues Earnings Results

Bio-Path (NASDAQ:BPTHGet Free Report) issued its earnings results on Wednesday. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.02, MarketWatch Earnings reports. During the same quarter in the prior year, the company earned ($0.49) earnings per share.

Bio-Path Stock Performance

Shares of BPTH opened at $0.54 on Friday. The company has a 50 day moving average price of $0.50 and a 200-day moving average price of $0.95. Bio-Path has a fifty-two week low of $0.32 and a fifty-two week high of $2.35. The stock has a market capitalization of $6.67 million, a PE ratio of -0.26 and a beta of 1.11.

Analysts Set New Price Targets

Separately, started coverage on shares of Bio-Path in a research report on Thursday. They issued a “sell” rating for the company.

View Our Latest Stock Analysis on BPTH

Institutional Investors Weigh In On Bio-Path

Hedge funds have recently modified their holdings of the business. Citadel Advisors LLC purchased a new stake in shares of Bio-Path in the 3rd quarter worth approximately $35,000. Virtu Financial LLC purchased a new stake in Bio-Path during the first quarter valued at approximately $38,000. Finally, Renaissance Technologies LLC purchased a new stake in Bio-Path during the second quarter valued at approximately $70,000. Hedge funds and other institutional investors own 5.74% of the company’s stock.

Bio-Path Company Profile

(Get Free Report)

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

Featured Stories

Earnings History for Bio-Path (NASDAQ:BPTH)

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with's FREE daily email newsletter.